Ceftazidime-Avibactam for Treating Urinary Tract Infections from Carbapenem-Resistant Bacteria
Author Information
Author(s): Muacevic Alexander, Adler John R, Dobhal Shipra, Sen Manodeep, Yadav Harshita, Agarwal Jyotsana, Das Anupam, Chandra Abhilash, Srivastava Alok, Nath Soumya
Primary Institution: Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, IND
Hypothesis
The study aims to test the efficacy of ceftazidime-avibactam in urinary isolates of carbapenem-resistant Enterobacterales.
Conclusion
Ceftazidime-avibactam alone showed high in-vitro resistance, but its combination with aztreonam demonstrated good susceptibility.
Supporting Evidence
- 28.1% of processed samples showed significant growth.
- 15.3% of isolates were Enterobacterales resistant to imipenem/meropenem.
- 91.9% in vitro resistance to ceftazidime-avibactam was observed.
- 100% susceptibility was noted in a subset when ceftazidime-avibactam was combined with aztreonam.
Takeaway
Doctors are trying a new medicine called ceftazidime-avibactam to help treat infections caused by superbugs that don't respond to regular antibiotics, and it works better when mixed with another medicine.
Methodology
This was a prospective, observational study conducted over six months, processing urine samples for identification and antimicrobial susceptibility testing.
Limitations
The study was conducted in a single hospital, which may not represent community-acquired infections, and genotypic testing was limited to a subset of isolates.
Participant Demographics
The majority of participants were inpatients, with a higher prevalence of CRE in men aged 41-60 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website